1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

‘Putting Electric Motors Into Classic Cars’ – Burt Sets Out European Potential Of Value Added Medicines

Medicines For Europe’s New Sector Chief Highlights Opportunities For Innovation

 
• By Dave Wallace

Pharmanovia CEO James Burt recently took over as chair of Medicines for Europe’s value added medicines sector group. In an exclusive interview with Generics Bulletin, he looks to the future for innovation around known medicines in Europe, including landmark EU legislation on the horizon and the importance of stakeholder dialogue throughout the supply chain.

James Burt at Medicines For Europe's VAM conference, November 2023
James Burt addresses Medicines for Europe’s fifth annual value added medicines conference • Source: Medicines for Europe

Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in November, not only marked a milestone for the sector in Europe – in the form of EU legislative efforts to recognise the value of repurposed medicines with a proposed four-year period of data exclusivity protection for new indications (Also see "European Opportunities Loom For Value Added Medicines" - Generics Bulletin, 15 November, 2023.) – but also marked the transition from one Medicines for Europe value added medicines sector chair to the next.

At the conference, James Burt – formerly head of the EMENA region at Accord Healthcare, now CEO of value added medicines specialist Pharmanovia – took over the role from Viatris’s Arun Narayan (see sidebar)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.